Inogen, Inc. — Q1 2017 Form 10-Q
Reporting period: Three months ended March 31, 2017; comparisons are with Q1 2016 unless stated otherwise. Financial statement amounts are in millions of dollars unless noted. Inogen develops, manufactures, sells, and rents portable oxygen concentrators.
Key financial results
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Total revenue | $52.5 | $43.0 | +22.1% |
| Sales revenue | $46.0 | $32.8 | +40.1% |
| Rental revenue | $6.5 | $10.2 | -35.8% |
| Gross profit / gross margin | $25.7 / 49.0% | $21.3 / 49.5% | Gross profit +21.0% |
| Operating income / operating margin | $5.6 / 10.6% | $3.3 / 7.6% | Operating income +70.0% |
| Net income / net margin | $5.9 / 11.3% | $2.5 / 5.9% | Net income +135.3% |
| Diluted EPS | $0.27 | $0.12 | — |
| Operating cash flow | $13.2 | $4.8 | +$8.4 |
Sales growth reflected approximately 25,600 systems sold, versus 17,000 a year earlier, driven by domestic and international business-to-business demand and higher U.S. direct-to-consumer sales. Sales gross margin improved to 52.3% from 49.7%, principally on lower product costs; rental gross margin fell to 25.9% from 48.9% as reimbursement and rental revenue per patient declined. Adjusted EBITDA, a non-GAAP measure, was $10.9 million versus $8.1 million.
Financial position and liquidity
- At March 31, cash and cash equivalents were $105.1 million and marketable securities were $23.1 million; net working capital was $151.2 million.
- Total liabilities were $34.9 million, including $25.3 million of current liabilities. The company had no outstanding borrowings and reported $15.0 million available under its revolving credit facility.
- Operating cash flow was $13.2 million; investing activities used $3.8 million and financing activities provided $2.8 million. Cash increased $12.3 million during the quarter.
- Management said existing liquidity, available credit, and expected operating cash flows should cover projected operating and investing needs for at least the next 12 months. This is a forward-looking expectation, not a guarantee.
Material changes, outlook, and notable items
- Management expects 2017 rental revenue to decline approximately 25%–30% from 2016, citing reimbursement reductions, fewer rental patients, and a strategic focus on product sales. Rental patients were approximately 32,600 at quarter-end, down from 33,200 a year earlier; 17.2% were in capped rental status, versus 12.9% a year earlier.
- Medicare rate reductions and related private-payor responses pressured rental results. The quarter included $0.2 million of expected Cures Act reimbursement, with additional payments expected in Q2 and Q3 2017. The company said the legislation also produced a nonrecurring $2.0 million rental-revenue benefit in Q4 2016.
- Management anticipated higher direct-to-consumer sales in the second half of 2017 than the first half, while noting possible short-term productivity disruption from a planned Q2 CRM system implementation. It also planned to expand its Cleveland-area facility and sales/customer-service workforce, and expected higher operating expenses.
- Income taxes included a $2.2 million discrete tax benefit related to stock-based compensation, substantially affecting the reported tax benefit and net income. The filing cautions that the effective tax rate may vary with stock price and award activity.
- On May 4, 2017, after quarter-end, Inogen acquired Dutch distributor MedSupport Systems B.V. for approximately $5.6 million in cash. The acquisition is intended to add European customer support and repair capacity; purchase accounting was incomplete when the filing was issued.
- Outstanding vendor purchase orders were approximately $47.7 million. Inogen also disclosed two contested patent-related lawsuits: Separation Design Group and CAIRE. The filing describes potential litigation costs and business disruption but does not provide a clear estimate of possible loss.
- Other exposures include Medicare and Medicaid reimbursement changes, competitive bidding and prior-authorization rules, customer and supplier concentration, foreign exchange, regulatory compliance, and product/IP litigation. A single customer represented more than 10% of net receivables; one customer also exceeded 10% of quarterly revenue. Three vendors accounted for 18.8%, 11.6%, and 10.9% of raw-material purchases.
Most important facts for investors to verify
- Whether system-sales growth and improved sales margins can offset the expected rental-revenue decline and higher growth-related expenses.
- The timing and collection of Cures Act reimbursement amounts and the effects of current and future Medicare, competitive-bidding, and private-payor rates.
- Receivable quality and concentration, including extended payment terms for a large customer and the adequacy of related credit insurance.
- MedSupport’s final purchase-price adjustment, purchase accounting, integration costs, and contribution to European operations.
- Developments and potential financial consequences of the SDGIP and CAIRE lawsuits, as well as European product certification timing.
- Cash-flow sustainability, vendor commitments, and compliance with credit-facility covenants. The filing reported covenant EBITDA of $46.4 million against a $12.5 million minimum and tangible net worth of $192.6 million against a $90.0 million minimum.